Hologic, Inc. (NASDAQ:HOLX) Shares Sold by Envestnet Portfolio Solutions Inc.

Envestnet Portfolio Solutions Inc. cut its holdings in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 57.5% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 6,205 shares of the medical equipment provider's stock after selling 8,412 shares during the period. Envestnet Portfolio Solutions Inc.'s holdings in Hologic were worth $383,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in HOLX. LaFleur & Godfrey LLC lifted its holdings in Hologic by 2.9% in the fourth quarter. LaFleur & Godfrey LLC now owns 130,373 shares of the medical equipment provider's stock valued at $9,399,000 after acquiring an additional 3,655 shares during the period. New York Life Investment Management LLC increased its holdings in shares of Hologic by 1.0% during the 4th quarter. New York Life Investment Management LLC now owns 35,012 shares of the medical equipment provider's stock valued at $2,524,000 after purchasing an additional 361 shares in the last quarter. Mn Services Vermogensbeheer B.V. lifted its stake in shares of Hologic by 1.8% in the 4th quarter. Mn Services Vermogensbeheer B.V. now owns 93,660 shares of the medical equipment provider's stock valued at $6,752,000 after purchasing an additional 1,700 shares during the period. Oppenheimer & Co. Inc. lifted its stake in shares of Hologic by 6.3% in the 4th quarter. Oppenheimer & Co. Inc. now owns 21,225 shares of the medical equipment provider's stock valued at $1,530,000 after purchasing an additional 1,250 shares during the period. Finally, Proficio Capital Partners LLC purchased a new stake in Hologic during the fourth quarter worth $4,215,000. 94.73% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, Director Martin D. Madaus bought 5,445 shares of the stock in a transaction dated Wednesday, May 7th. The shares were acquired at an average cost of $55.24 per share, for a total transaction of $300,781.80. Following the acquisition, the director directly owned 5,445 shares in the company, valued at approximately $300,781.80. This trade represents a ∞ increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 1.88% of the company's stock.

Analyst Upgrades and Downgrades

HOLX has been the topic of several recent analyst reports. Wall Street Zen lowered shares of Hologic from a "buy" rating to a "hold" rating in a research note on Monday, May 5th. Citigroup reduced their price target on Hologic from $80.00 to $70.00 and set a "neutral" rating for the company in a report on Tuesday, March 4th. Raymond James Financial reiterated an "outperform" rating and set a $71.00 price target (down previously from $90.00) on shares of Hologic in a research report on Friday, May 2nd. Royal Bank Of Canada dropped their price objective on Hologic from $75.00 to $70.00 and set a "sector perform" rating on the stock in a report on Friday, May 2nd. Finally, Stephens reduced their target price on Hologic from $77.00 to $70.00 and set an "overweight" rating for the company in a research note on Tuesday, May 13th. Twelve analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of "Hold" and an average price target of $77.42.

Hologic Price Performance

Shares of NASDAQ:HOLX traded up $0.15 during trading on Monday, reaching $65.16. The stock had a trading volume of 1,590,544 shares, compared to its average volume of 2,366,784. The company has a debt-to-equity ratio of 0.54, a quick ratio of 2.52 and a current ratio of 3.24. Hologic, Inc. has a 1-year low of $51.90 and a 1-year high of $84.67. The stock has a market cap of $14.52 billion, a PE ratio of 27.49, a PEG ratio of 2.38 and a beta of 0.55. The business has a fifty day moving average price of $60.00 and a 200-day moving average price of $63.90.

Hologic (NASDAQ:HOLX - Get Free Report) last announced its quarterly earnings data on Thursday, May 1st. The medical equipment provider reported $1.03 earnings per share for the quarter, beating analysts' consensus estimates of $1.02 by $0.01. Hologic had a return on equity of 19.71% and a net margin of 13.83%. The company had revenue of $1.01 billion for the quarter, compared to analyst estimates of $1 billion. During the same quarter last year, the firm posted $1.03 EPS. The firm's revenue for the quarter was down 1.2% on a year-over-year basis. On average, equities analysts forecast that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.